[Risk Factor of Cutaneous Symptoms Associated with Enfortumab Vedotin for Urothelial Carcinoma]
{{output}}
In 2021, Enfortumab Vedotin (EV) was approved for the treatment of locally advanced and metastatic urothelial carcinoma (UC) in Japan. Some patients require withdrawal or dose reduction due to cutaneous symptoms associated with EV treatment. Currently, the onl... ...
